Drugs / SIM0718
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06488755 | Jun 2024 → Feb 2027 expected | asthma | Simcere Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06477835 Comparator | Jul 2024 → Nov 2025 | atopic eczema | Simcere Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06488755 ↗ |
| Route | Subcutaneous | “All subjects were dosed SC at 300 mg SIM0718.” NCT06477835 ↗ |